Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Twist Bioscience (TWST) to $54 from $48 and keeps an Outperform rating on the shares. The firm said Q1 results beat expectations and saw encouraging gross margins progress.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
Questions or Comments about the article? Write to editor@tipranks.com